<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3>SECURITIES AND
EXCHANGE COMMISSION<BR>WASHINGTON, D. C. 20549 </FONT></H1>


<!-- MARKER FORMAT-SHEET="Head Major Center Bold" FSL="Default" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3>FORM 8-K </FONT></H1>

<!-- MARKER FORMAT-SHEET="Page Rule Single" FSL="Default" -->
     <HR ALIGN=LEFT WIDTH=100% SIZE=1 NOSHADE>

<!-- MARKER FORMAT-SHEET="Head Minor Center" FSL="Default" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CURRENT REPORT<BR>PURSUANT TO SECTION 13
OR 15(d) OF<BR> THE SECURITIES EXCHANGE ACT OF 1934 </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center" FSL="Default" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Date of Report (Date of earliest event reported) <BR><B>February 25, 2005 </B></FONT></P>


<!-- MARKER FORMAT-SHEET="Head Minor Center Bold" FSL="Default" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=3><B>MedImmune, Inc.</B><BR>(Exact
name of registrant as specified in its charter)</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" WIDTH="600">
<TR VALIGN=Bottom>
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
     <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH></TR>
<TR VALIGN=Bottom>
     <TD WIDTH="33%" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delaware</FONT></TD>
     <TD WIDTH="33%" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0-19131</FONT></TD>
     <TD WIDTH="34%" ALIGN="CENTER"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>52-1555759</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(State or other jurisdiction of</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(Commission File No.)</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(I.R.S. Employer Identification No.)</FONT></TD></TR>
<TR VALIGN=Bottom>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;incorporation or organization)</FONT></TD>
     <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD></TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Head Minor Center" FSL="Default" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>One MedImmune Way,
 Gaithersburg, MD 20878</B><BR>(Address of principal executive offices) (Zip Code) </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Large Indent" FSL="Default" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Registrant&#146;s
telephone number, including area code (301) 398-0000 </FONT></P>
<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (<I>see
</I>General Instruction A.2. below): </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;|_|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;|_| Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;|_|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Indent" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;|_|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) </FONT></P>

<!-- MARKER PAGE="sheet: 4; page: 4" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>



<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<A NAME=A001></A>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Section&nbsp;1 &#150;
Registrant&#146;s Business and Operations </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<A NAME=A002></A>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item&nbsp;1.01 Entry
into a Material Definitive Agreement. </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>MedImmune, Inc.
(&#147;MedImmune&#148; or the &#147;Company&#148;) entered into a Distribution Agreement
with Abbott International, LLC, an affiliate of Abbott Laboratories (&#147;Abbott&#148;),
as of December 1, 1997, which was subsequently amended as of April 28, 1999, October 8,
1999 and July 1, 2003, pursuant to which Abbott has been exclusively distributing
Synagis&reg; (palivizumab), a monoclonal antibody (MAb) directed against respiratory
syncytial virus (RSV), outside of the United States. On February 25, 2005, the Company and
Abbott executed an Amended and Restated Distribution Agreement, effective as of February
23, 2005, to include the exclusive distribution of Numax&#153;, an investigational
second-generation MAb developed by the Company and also directed against RSV, if and to
the extent approved for marketing by regulatory authorities outside of the United States. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Synagis is currently approved for
marketing in 61 countries outside of the United States. Under the terms of the agreement,
as amended and restated, Abbott will continue to distribute and market the current,
lyophilized (freeze-dried) version of Synagis outside of the United States and will be
working with the Company to obtain approval for and distribute the liquid formulation of
Synagis outside of the United States for the prevention of RSV. In addition, Abbott will
be working to secure regulatory approval of Numax outside of the United States and, if and
when such approval is received, will distribute and market Numax outside of the United
States. Abbott will purchase Synagis and Numax from MedImmune at a price that is based on
a percentage of Abbott&#146;s sales to its customers. The agreement generally provides for
MedImmune to bear clinical trial costs associated with product development outside of the
United States and for Abbott to bear the cost of any studies required for obtaining or
maintaining regulatory approval outside of the United States. MedImmune also has the right
to co-promote Numax in up to 7 countries outside of the United States with Abbott in
certain circumstances. The foregoing summary of the amended and restated distribution
agreement is subject to, and qualified in its entirety by, the distribution agreement
which will be filed as an exhibit to the Company&#146;s Annual Report on Form 10-K for the
year ended December 31, 2004. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Other than this Distribution
Agreement and a separate co-promotion agreement with the Ross Products Division of Abbott
Laboratories pursuant to which such division provides sales support for Synagis in the
United States, the Company has no other material relationship with Abbott. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<A NAME=A003></A>
<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item&nbsp;7.01
Regulation FD Disclosure. </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The Company furnishes a copy of the
press release issued on February 28, 2005, attached as <U>Exhibit 99.1</U> and
incorporated by reference herein. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" -->
<A NAME=A004></A>

<H1 ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Item 9.01 Financial Statements and Exhibits.</FONT></H1>
 <P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(c) Exhibits.</FONT></P>

<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exhibit</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Description</U> </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 3 Left" FSL="Default" -->

<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 Press Release issued February 28, 2005, titled "MedImmune Expands Ex-U.S. Distribution
                           Agreement with Abbott for Monoclonal Antibodies Against RSV." </FONT> </P>













<!-- MARKER PAGE="sheet: 5; page: 5" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>


<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>SIGNATURE </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold" FSL="Default" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MEDIMMUNE, INC. </FONT></H1>

<!-- MARKER FORMAT-SHEET="Signature (Single)" FSL="Project" -->
<TABLE WIDTH=100% CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=10%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=50%><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B></B><BR><BR>
<BR>By: /s/: Atul Saran<BR>&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;<BR>
Name:  Atul Saran<BR>Title:  Director, Legal Affairs &amp; Assistant Secretary</FONT></TD>
</TR>
</TABLE>
<BR>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Project" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Date:  March 3, 2005 </FONT></P>


<!-- MARKER PAGE="sheet: 6; page: 6" -->
<HR SIZE=5 COLOR=GRAY NOSHADE>


<!-- MARKER FORMAT-SHEET="Head Major Center Bold" FSL="Default" -->
<A NAME=A006></A>
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>EXHIBIT INDEX </FONT></H1>

<!-- MARKER FORMAT-SHEET="Head Sub 2 Left" FSL="Default" -->
<A NAME=A007></A>
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exhibit</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Description</U> </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 3 Left" FSL="Default" -->
<A NAME=A014></A>
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 Press Release issued February 28, 2005, titled "MedImmune Expands Ex-U.S. Distribution
                           Agreement with Abbott for Monoclonal Antibodies Against RSV." </FONT> </P>



</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "f8kmarch3.htm", "description": "CO-PROMOTION RIGHTS TO NUMAX", "secsgml_size_bytes": 12152}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19131", "film-number": "05658336"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13
OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
February 25, 2005
MedImmune, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
0-19131
52-1555759
(State or other jurisdiction of
(Commission File No.)
(I.R.S. Employer Identification No.)
incorporation or organization)
One MedImmune Way,
 Gaithersburg, MD 20878
(Address of principal executive offices) (Zip Code)
Registrant's
telephone number, including area code (301) 398-0000
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|_|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|_| Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|_|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|_|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Section 1 –
Registrant's Business and Operations
Item 1.01 Entry
into a Material Definitive Agreement.
MedImmune, Inc.
("MedImmune" or the "Company") entered into a Distribution Agreement
with Abbott International, LLC, an affiliate of Abbott Laboratories ("Abbott"),
as of December 1, 1997, which was subsequently amended as of April 28, 1999, October 8,
1999 and July 1, 2003, pursuant to which Abbott has been exclusively distributing
Synagis® (palivizumab), a monoclonal antibody (MAb) directed against respiratory
syncytial virus (RSV), outside of the United States. On February 25, 2005, the Company and
Abbott executed an Amended and Restated Distribution Agreement, effective as of February
23, 2005, to include the exclusive distribution of Numax™, an investigational
second-generation MAb developed by the Company and also directed against RSV, if and to
the extent approved for marketing by regulatory authorities outside of the United States.
Synagis is currently approved for
marketing in 61 countries outside of the United States. Under the terms of the agreement,
as amended and restated, Abbott will continue to distribute and market the current,
lyophilized (freeze-dried) version of Synagis outside of the United States and will be
working with the Company to obtain approval for and distribute the liquid formulation of
Synagis outside of the United States for the prevention of RSV. In addition, Abbott will
be working to secure regulatory approval of Numax outside of the United States and, if and
when such approval is received, will distribute and market Numax outside of the United
States. Abbott will purchase Synagis and Numax from MedImmune at a price that is based on
a percentage of Abbott's sales to its customers. The agreement generally provides for
MedImmune to bear clinical trial costs associated with product development outside of the
United States and for Abbott to bear the cost of any studies required for obtaining or
maintaining regulatory approval outside of the United States. MedImmune also has the right
to co-promote Numax in up to 7 countries outside of the United States with Abbott in
certain circumstances. The foregoing summary of the amended and restated distribution
agreement is subject to, and qualified in its entirety by, the distribution agreement
which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the
year ended December 31, 2004.
Other than this Distribution
Agreement and a separate co-promotion agreement with the Ross Products Division of Abbott
Laboratories pursuant to which such division provides sales support for Synagis in the
United States, the Company has no other material relationship with Abbott.
Item 7.01
Regulation FD Disclosure.
The Company furnishes a copy of the
press release issued on February 28, 2005, attached as
Exhibit 99.1
and
incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.
Exhibit
Description
99.1                  
 Press Release issued February 28, 2005, titled "MedImmune Expands Ex-U.S. Distribution
                           Agreement with Abbott for Monoclonal Antibodies Against RSV."
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MEDIMMUNE, INC.
By: /s/: Atul Saran
——————————————
Name:  Atul Saran
Title:  Director, Legal Affairs & Assistant Secretary
Date:  March 3, 2005
EXHIBIT INDEX
Exhibit
Description
99.1                  
 Press Release issued February 28, 2005, titled "MedImmune Expands Ex-U.S. Distribution
                           Agreement with Abbott for Monoclonal Antibodies Against RSV."